Brief: Calithera Biosciences Announces First Patient Enrolled In Phase 2 Clinical Trial Of Sapanisertib

Calithera Biosciences

06/07/2022 21:18

July 6 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN
PHASE
2 CLINICAL TRIAL OF SAPANISERTIB IN RELAPSED/REFRACTORY NRF2
(NFE2L2)-MUTATED SQUAMOUS NON-SMALL CELL LUNG CANCER
    * CALITHERA BIOSCIENCES INC - PLAN TO SHARE DATA FROM TRIAL
BY Q1
OF 2023
    * CALITHERA - DATA FROM THIS STUDY COULD POSITION CALITHERA
TO
INITIATE A STUDY WITH REGISTRATIONAL INTENT IN
BIOMARKER-SPECIFIC SQNSCLC POPULATIONS

Source text for Eikon:  ID:nGNX7hWpbd 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))